Feasibility of bevacizumab (BEV) plus chemotherapy in heavily pretreated ovarian cancer (OC) patients (pts): A retrospective study. Background: Rising serum cancer antigen 125 (CA-125) trends within ...

Efficacy of pegylated liposomal doxorubicin (PLD) and oxaliplatin (Ox) in pre-treated advanced epithelial ovarian cancer (EOC) in relation to BRCA status No significant financial relationships to ...

Recurrent epithelial ovarian carcinoma is considered an incurable disease, and second-line chemotherapy is mainly considered for palliation of symptoms and extension of survival. There are a growing ...

Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive ...

The value of the serum tumour marker CA 125 to date has been in the monitoring of ovarian cancer patients for response to therapy and for recurrence of disease. However, despite the availability of ...

Cancer Antigen 125 (CA-125) testing shows 23% lower odds of elevated levels in American Indian and Black patients with ovarian cancer compared with White patients. Patients with false-negative CA-125 ...

Current CA-125 thresholds may miss ovarian cancer in racially diverse patients, delaying treatment initiation and contributing to health disparities. Original CA-125 studies were conducted on ...